The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and ...

Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with the ...